• Home
  • > Media & Investors
  • > Media Relations
  • > Press Releases
  • > Daiichi Sankyo to transfer marketing authorization rights for four diagnostic imaging agents in Japan to GE Healthcare

For Immediate Release

2019.06.25

Daiichi Sankyo
GE Healthcare

Daiichi Sankyo to transfer marketing authorization rights for four diagnostic imaging agents in Japan to GE Healthcare

Tokyo, Japan and Chicago, US (June 25, 2019) – Daiichi Sankyo Company, Limited (Head Office: Chuo-ku Tokyo; hereafter, Daiichi Sankyo) and GE Healthcare (Head Office: Chicago, US) have agreed[1] that, Daiichi Sankyo will return the exclusive development and marketing rights in Japan for four approved diagnostic imaging agents[2] to GE Healthcare and transfer marketing authorization rights in Japan to GE Healthcare Pharma Limited[3] (GE Healthcare Pharma).   

 

The four diagnostic imaging agents to be transferred to GE Healthcare by Daiichi Sankyo are:

Product name

Product description

Omnipaque®

Nonionic X-ray contrast agent

Omniscan®

Linear, nonionic magnetic resonance imaging contrast agent

Visipaque®

Nonionic, iso-osmolar X-ray contrast agent

Sonazoid®

Ultrasound contrast agent

 

 

Daiichi Sankyo and GE Healthcare have collaborated since 1987 when they started sales of Omnipaque® in Japan. Throughout this transfer, both companies are committed to continue providing reliable supply to medical facilities.

 

Based on this agreement*, Daiichi Sankyo and GE Healthcare will closely collaborate on the transfer of marketing authorization rights which is expected to be complete in March 2020. GE Healthcare Pharma will then be responsible for all aspects of commercialization, regulatory, medical and safety of these products in Japan. Daiichi Sankyo will continue to distribute the products to drug whole sellers until March 2022, after which they will transfer these operations to GE Healthcare Pharma.

 

Through this transaction, GE Healthcare will strengthen its position as a leading medtech and diagnostics innovator at the center of an ecosystem striving for precision health. The company is working to improve quality of healthcare and bring more precise diagnoses for patients in Japan, the third largest contrast media market globally[4]. Daiichi Sankyo will be increasing investments in its oncology pipeline in order to realize its 2025 vision of becoming a “Global Pharma Innovator with competitive advantage in oncology,” providing new treatment options to more patients faster.

 

[1] Subject to customary regulatory approvals and closing conditions.

[2] Diagnostic contrast imaging agents are administered to patients prior to Computed Tomography, Magnetic Resonance Imaging or Ultrasound scans to improve quality of images that radiologists use to diagnose and monitor disease.

[3] GE Healthcare Pharma Limited is newly established an entity of GE Healthcare to run the business of its Pharmaceutical Diagnostics business in Japan.

[4] CMIG/IMS (industry data).

 

About GE Healthcare
GE Healthcare is the $19.8 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services.  With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers and life sciences companies around the world.  Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news, or visit our website https://corporate.gehealthcare.com/en/ for more information.

 

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com

 

Contact

DAIICHI SANKYO COMPANY, LIMITED

Corporate Communications Department

Phone´╝Ü+81-3-6225-1126

GE Healthcare Japan

Corporate Communications

Email: Gehcj.commc@ge.com